Onconova stock: buy or sell?

ONTX stock price: $0.48 -2.04% At close on February 26th, 2020

Updated on:
February 26th, 2020


After sliding a bloodcurdling -6.12% yesterday, Onconova Therapeutics closed today at $0.48 and slipped an awful -2.04%. Wednesday was the fourth red session in a row, sliding in full a -11.32%. On February 19th ONTX boosted an astounding 5.66%.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer.

Should I buy Onconova stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Onconova Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ONTX will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Onconova Therapeutics stock a buy?

Financial institutions and banks post stock ratings everyday. Unfortunately, we couldn't detect any rating for ONTX stock for the last month.

Onconova stock analysis

Daily outlook

After sliding a bloodcurdling -6.12% yesterday, Onconova Therapeutics closed today at $0.48 and slipped an awful -2.04%.

After sliding a bloodcurdling -6.12% yesterday, Onconova Therapeutics closed today at $0.48 and slipped an awful -2.04%.

ONTX stock chart (daily)

Weekly outlook

Onconova Therapeutics shares plunged -9.43% this week, ending at $0.48. By mid February ONTX skyrocketed an amazing 7.55% in just one week.

In a weekly time frame, Onconova Therapeutics stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, ONTX might consolidate in a flat-base, waiting to break out over or down under . Since this week when SMA10w and SMA20w crossed up, ONTX price slipped $-0.05 per share (-9.43%).

ONTX stock chart (weekly)

Onconova stock price history

Onconova IPO was on July 25th, 2013 at $3,750.00 per share1. Since then, ONTX stock lost a -100.00%, with a yearly average of -16.70%.

1: Adjusted price after possible price splits or reverse-splits.

Onconova stock historical price chart

ONTX stock reached 52-week highs on March at $4.83, and all-time highs 2013-10-04 with a price of 4669.5.

Onconova stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price target for Onconova Therapeutics stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

Onconova disappointed experts on March when it reported an Earnings per Share (EPS) of $-0.85 when the analysts' forecast was $-1.09.
ONTX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Onconova Therapeutics annual sales climbed an extraordinary 56.04% to $1.23 million dollars from $0.79 marked in 2017. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) boosted a 1,385.92% to -1,675.33%.

ONTX annual Sales and Income evolution
2013$4.75 M-$-64.86 M-1365.5%-
2014$0.80 M-83.16%$-63.68 M-7960.2%-1.82%
2015$11 M1,332.00%$-23.98 M-209.3%-62.35%
2016$5.55 M-51.59%$-19.67 M-354.6%-17.98%
2017$0.79 M-85.81%$-24.09 M-3061.2%22.50%
2018$1.23 M56.04%$-20.57 M-1675.3%-14.61%

Quarterly financial results

Onconova Therapeutics posted $0.06 million in revenues for 2018-Q4, a -50.83% decline compared to previous quarter. Reported quarter income marked $-5.65 million with a profit margin of -9,577.97%. Profit margin plunged a -5,121.30% compared to previous quarter when profit margin was -4,456.67%. When comparing turnover to same quarter last year, Onconova sales marked a chilling slide and collapsed a -58.74%. Looking back to recent quarterly results, Onconova Therapeutics posted 3 positive quarters in a row.
ONTX quarterly Sales and Income evolution
2017-Q1$0.21 M-$-8.34 M-3971.4%-
2017-Q2$0.32 M54.29%$-2.58 M-796.3%-69.06%
2017-Q3$0.11 M-66.05%$-6.96 M-6328.2%169.81%
2017-Q4$0.14 M30.00%$-6.21 M-4340.6%-10.83%
2018-Q1$0.56 M294.41%$-5.09 M-902.5%-18.00%
2018-Q2$0.49 M-14.01%$-4.48 M-924.5%-11.91%
2018-Q3$0.12 M-75.26%$-5.35 M-4456.7%19.27%
2018-Q4$0.06 M-50.83%$-5.65 M-9578.0%5.67%

Onconova ownership

When you are planning to invest in a stock, it's worth to overview its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Onconova Therapeutics, 1.10% of all outstanding shares are owned by its staff.

In case of Onconova stock, 13.33% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ONTX stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Onconova Therapeutics:

Market cap$66.6 M
Total shares138.7 M
Float shares7.2 M
  - Institutional holdings (%)13.3%
  - Insider holdings (%)1.1%
Shares in short selling0.0%

Onconova summary

Wednesday, February 26th, 2020
Day range$0.46 - $0.52
Previous close$0.49
Session gain-2.04%
Average true range$0.09
50d mov avg$0.42
100d mov avg$0.47
200d mov avg$1.57
Daily patternlt01a
Weekly pattern lt06a

Onconova performance

To measure stock performance is always good to compare with competitors or related stocks. We picked as the bechmarking frame for Onconova Therapeutics stock.
ONTXOnconova Therapeu...152.63%-80.00%-85.88%

Onconova competitors

Unfortunately, we could not find any public company that could be defined as Onconova Therapeutics competitor. This doesn't mean Onconova Therapeutics does not have any competitor in the market, it's just we could not detected it.